Control: Clinical Trials

16 trials of Control, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 terminated. 16 Phase 2, 7 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Terminated 16
Phase 37Terminated 7
Phase 14Terminated 4

Follow Control: new trials by email Literature Review of Control trials Research Report on Control

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral Naltrexone In Pediatric Eating Disorders
Naltrexone Hydrochloride, Control - Anorexia Nervosa/Bulimia, Anorexia in Adolescence
Phase 2 / Phase 3TerminatedRosemary Claire Roden92022-04-222025-08-19
Ivermectin in Adults With Severe COVID-19.
Ivermectin, Placebo - Covid19, Severe Acute Respiratory Syndrome
Phase 2TerminatedCES University752020-12-102022-01-04
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Reparixin, Standard of care - Severe Pneumonia
Phase 2 / Phase 3TerminatedDompé Farmaceutici S.p.A562020-05-052024-01-08
Nitrite Infusion in Islet Cell Transplantation
Control, Pre-Isolation Infusion, Post-Isolation Infusion - Diabetes
Phase 2TerminatedUniversity of Alabama at Birmingham42017-05-072020-10-29
Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea
Ketamine, Control - Sleep Apnea, Obstructive Sleep Apnea
Phase 2 / Phase 3TerminatedUniversity of Alabama at Birmingham92016-06-022019-12-19
Fenofibrate and Propranolol in Burn Patients
Fenofibrate, Placebo, Propranolol - Burn
Phase 2 / Phase 3TerminatedThe University of Texas Medical Branch, Galveston182015-11-012019-11-29
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
Reparixin, Control - Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction
Phase 2TerminatedDompé Farmaceutici S.p.A402015-03-102025-01-07
CO as a Stimulant for Mitochondrial Biogenesis in Human Cardiac Muscle
200ppm CO for one hour, Control - Cardiac Disease, Mitochondrial Biogenesis
Phase 1 / Phase 2TerminatedJohn J Freiberger12014-02-012016-05-19
Propranolol in Severely Burned Children
Propranolol, Placebo - Burn
Phase 2 / Phase 3TerminatedThe University of Texas Medical Branch, Galveston632013-12-012019-09-24
Protective Effects of Propranolol in Adults
Propranolol, Placebo - Burn
Phase 2 / Phase 3TerminatedThe University of Texas Medical Branch, Galveston472013-07-012019-11-29
Benefit and Tolerability of a Probiotic Product in Infants With Abdominal Discomfort
Probiotics, Control - Abdominal Discomfort
Phase 2TerminatedProbi AB52013-04-012016-09-22
Techniques to Enhance Patient Comfort in Sedation-risk Free Colonoscopy
Warm water, Control - Screening of Colonic Polyps
Phase 1 / Phase 2TerminatedVA Greater Los Angeles Healthcare System852007-12-012015-12-15
Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis
PH-10 (rose bengal disodium 0.001%), Control - Plaque Psoriasis
Phase 2TerminatedProvectus Pharmaceuticals62007-11-012021-12-16
The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
Pegaptanib Sodium, Control - Cystoid Macular Edema
Phase 1 / Phase 2TerminatedJohns Hopkins University12006-07-012008-05-12
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
Pegaptanib sodium, Control - Cystoid Macular Edema
Phase 1 / Phase 2TerminatedJohns Hopkins University42006-06-012008-05-12
Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI - Burns
Phase 2 / Phase 3TerminatedThe University of Texas Medical Branch, Galveston11262004-01-012019-11-29

Conditions studied

Burns (4)  ·  COVID-19 (2)  ·  Macular Edema (2)  ·  Reperfusion Injury (2)  ·  Anorexia Nervosa (1)  ·  Bulimia (1)  ·  Bulimia Nervosa (1)  ·  Diabetes Mellitus (1)  ·  Feeding and Eating Disorders (1)  ·  Heart Diseases (1)  ·  Impulsive Behavior (1)  ·  Insulin Resistance (1)  ·  Motor Activity (1)  ·  Pneumonia (1)  ·  Pneumonia, Viral (1)

Sponsors

The University of Texas Medical Branch, Galveston (4)  ·  Dompé Farmaceutici S.p.A (2)  ·  Johns Hopkins University (2)  ·  University of Alabama at Birmingham (2)  ·  CES University (1)  ·  John J Freiberger (1)  ·  Probi AB (1)  ·  Provectus Pharmaceuticals (1)  ·  Rosemary Claire Roden (1)  ·  VA Greater Los Angeles Healthcare System (1)

Countries

United States (12)  ·  Belarus (1)  ·  Brazil (1)  ·  Canada (1)  ·  Colombia (1)  ·  Germany (1)  ·  Italy (1)  ·  Russia (1)

Top investigators

David N Herndon, MD (4)  ·  Alberto Zangrillo, MD PhD (1)  ·  Amir Larian, MD (1)  ·  Blair Smith, MD (1)  ·  Diana V. Do, MD (1)  ·  Felix W. Leung, MD (1)  ·  Francisco L Ochoa-Jaramillo, MD; MSc (1)  ·  Lorenzo Piemonti, MD PhD (1)  ·  Oliver D. Schein, MD, MPH, MBA (1)  ·  Peter A Nagi, MD (1)  ·  Rosemary C Roden, MD (1)  ·  Sergey Vladimirovich Zhuravel, MD (1)

Results publications

PMID 19734776, PMID 20881067, PMID 22463890, PMID 22606232, PMID 22895351, PMID 23150682, PMID 23303450, PMID 24009246, PMID 24298851, PMID 24655871, PMID 24824900, PMID 24918945, PMID 25211297, PMID 25514427, PMID 25807408, PMID 27171844, PMID 27433905, PMID 28240622, PMID 35618953, PMID 36167287

NIH funding

P50GM060338 (1)